ObjectiveTo evaluate the real-world efficacy and safety of cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4) in combination with chemotherapy with or without bevacizumab for cervical cancer and to identify potential biomarkers.MethodsThis preliminary report analyzes the first 51 consecutive patients from a protocol-driven observational cohort initiating cadonilimab (≥2 cycles) between June 2022 and August 2025. The treatment regimens were: cadonilimab + chemotherapy + bevacizumab (n=22), cadonilimab + chemotherapy (n=24), or cadonilimab alone (n=5).
Standardized data collection included clinicopathological variables, peripheral blood biomarkers, and protocol-defined tumor assessments (RECIST v1.1 every 6 weeks). Interim efficacy endpoints (objective response rate [ORR], disease control rate [DCR], median progression-free survival [mPFS]) and safety (CTCAE v5.0) were evaluated, with multivariate analyses to identify predictive factors.Interim resultsThe median follow-up was 11.0 months.
At the first tumor evaluation timepoint after completing two treatment cycles, 15 patients achieved complete response (CR), 22 patients achieved partial response (PR), and 9 patients achieved stable disease (SD), with an ORR of 72.5% and a DCR of 90.2%.
Frontiers in Immunology published a clinical update in Infectious Disease on 27 Apr 2026.
The item focuses on Real-world efficacy, safety, and associated biomarkers of cadonilimab in cervical cancer: a prospective observational study.
Review the original article for the full source wording and details.